$EXEL

WYSZOMIERSKI JACK L sold $198K of EXEL

WYSZOMIERSKI JACK L sold 3,925 shares of EXELIXIS, INC. (EXEL) at $50.55 ($0.20M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WYSZOMIERSKI JACK L
Published Jun 3, 2026, 10:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

This provides incremental sentiment information but no new fundamental data (no trial, approval, guidance, or deal).

02

Market read

Use mainly for sentiment/positioning checks rather than as a standalone catalyst.

03

What to watch

The filing doesn’t indicate whether additional buys/sells occurred around the same period or whether the director’s plan size is routine versus unusual.

Relevance 6/10Novelty 3/10Timing: Filed June 3; transaction executed June 1 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction disclosure (director selling shares).

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

SEC Form 4 shows an EXELIXIS director sold 3,925 shares in an open-market transaction under a 10b5-1 plan on June 1.

Expected impact

Likely limited/short-lived impact; any reaction should be muted given the pre-arranged 10b5-1 plan.

Evidence & confidence

The filing is a routine insider transaction with a stated pre-arranged 10b5-1 plan, providing disclosure but not a new operating or clinical catalyst.

Market effects

Minimal—this is company-specific insider disclosure without sector-wide regulatory/clinical implications.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 sale, the market may overreact; price action could revert if no other catalysts exist.

Key entities

  • EXELIXIS, INC.

    Company whose director disclosed an open-market sale of shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMed

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis (EXEL) announced a 3-month FDA review extension for zanzalintinib, now targeting March 3, 2027. The FDA requested updated safety and efficacy data. The drug, combined with atezolizumab, aims to treat metastatic colorectal cancer. Exelixis' approval prospects hinge on the full STELLAR-303 study data, which showed a statistically significant survival benefit in the overall population but not in a key subgroup.

$EXELMedAI 8/10

Does Extended FDA Review Change The Bull Case For Exelixis (EXEL)?

Exelixis (EXEL) announced a 3-month FDA review extension for its zanzalintinib plus atezolizumab NDA, moving the decision date to March 3, 2027. The delay is due to updated safety and efficacy data. Analysts highlight the impact on Exelixis' investment narrative, with near-term focus on the colorectal cancer decision. The company aims for $3.3B revenue and $1.3B earnings by 2029, with risks tied to CABOMETYX concentration and margin pressures.

$EXELMed

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis (EXEL) reported slower-than-expected revenue growth for CABOMETYX due to delayed treatment decisions in NET. The company maintains 47% new-patient market share and plans to launch zanza for colorectal cancer if approved. Exelixis expects CABOMETYX generics in 2031 and is investing in pipeline and share repurchases, with $600M remaining under its authorization.

$EXELLow

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC

The FDA extended its review of Exelixis' NDA for zanzalintinib plus atezolizumab to treat metastatic colorectal cancer, moving the PDUFA action date to March 3, 2027. The extension followed updated safety and efficacy data submission, classified as a major amendment. The NDA is supported by the STELLAR-303 trial, which showed a median OS of 10.9 months vs 9.4 months with regorafenib.